Company intelligence / Profile preview

Travanti Pharma

Minnesota, United Stateslinkedin.com ↗

Ownership: Private
Development stage: Phase 3

Overview

Travanti’s lead asset was a dexamethasone iontophoretic transdermal patch evaluated for pharmacokinetics and safety versus injection in healthy volunteers. The company developed proprietary wearable electronic drug delivery platforms with a focus on improving medication compliance and effectiveness. Clinical results were limited to early-stage studies before the company was acquired.

Therapeutic areas: OtherNeurology
Modalities: Transdermal drug delivery systems (notably iontophoretic patches)Small molecules (e.g., dexamethasone)
Industry: Biotech

Drug pipeline

1 asset

dexamethasone iontophoretic patch

Beyond the preview

Go deeper on Travanti Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Travanti Pharma.

Explore the full profile